Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (281-290 of 531) with videos related to

Pageof 54
Sort By:
Antimicrobial Agents and Chemotherapy|April 1, 1988
Effect of norfloxacin on theophylline pharmacokinetics at steady stateS K Bowles, Z Popovski, M J Rybak, et al.
Journal of the American Chemical Society|March 4, 2021
Catalytic Synthesis of Conjugated Azopolymers from Aromatic DiazidesJohn M Andjaba, Christopher J Rybak, Zhiyang Wang, et al.
Pharmacotherapy|March 7, 2012
Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohortRavina Kullar, Susan L Davis, Thomas N Taylor, et al.
Journal of Biomedical Nanotechnology|March 16, 2012
Effect of functionalization of carbon nanotubes with psychosine on complement activation and protein adsorptionMalgorzata J Rybak-Smith, Carla Tripisciano, Ewa Borowiak-Palen, et al.
Diagnostic Microbiology and Infectious Disease|February 16, 2007
Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agentsBrian T Tsuji, Michael J Rybak, Chrissy M Cheung, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2007
Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and functionWarren E Rose, Michael J Rybak, Brian T Tsuji, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazoleLisa M Avery, Molly E Steed, Ashley E Woodruff, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2018
Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closerSarah C J Jorgensen, Abdalhamid M Lagnf, Sahil Bhatia, et al.
The Journal of Infectious Diseases|September 1, 1993
Prospective evaluation of red man syndrome in patients receiving vancomycinT L O'Sullivan, M J Ruffing, K C Lamp, et al.
Diagnostic Microbiology and Infectious Disease|February 6, 2008
Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serumBrian T Tsuji, Steven N Leonard, Paul R Rhomberg, et al.
Pageof 54

Showing results (281-290 of 531) with videos related to

Sort By:
Pageof 54
Antimicrobial Agents and Chemotherapy|April 1, 1988
Effect of norfloxacin on theophylline pharmacokinetics at steady stateS K Bowles, Z Popovski, M J Rybak, et al.
Journal of the American Chemical Society|March 4, 2021
Catalytic Synthesis of Conjugated Azopolymers from Aromatic DiazidesJohn M Andjaba, Christopher J Rybak, Zhiyang Wang, et al.
Pharmacotherapy|March 7, 2012
Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohortRavina Kullar, Susan L Davis, Thomas N Taylor, et al.
Journal of Biomedical Nanotechnology|March 16, 2012
Effect of functionalization of carbon nanotubes with psychosine on complement activation and protein adsorptionMalgorzata J Rybak-Smith, Carla Tripisciano, Ewa Borowiak-Palen, et al.
Diagnostic Microbiology and Infectious Disease|February 16, 2007
Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agentsBrian T Tsuji, Michael J Rybak, Chrissy M Cheung, et al.
The Journal of Antimicrobial Chemotherapy|April 17, 2007
Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and functionWarren E Rose, Michael J Rybak, Brian T Tsuji, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazoleLisa M Avery, Molly E Steed, Ashley E Woodruff, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2018
Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closerSarah C J Jorgensen, Abdalhamid M Lagnf, Sahil Bhatia, et al.
The Journal of Infectious Diseases|September 1, 1993
Prospective evaluation of red man syndrome in patients receiving vancomycinT L O'Sullivan, M J Ruffing, K C Lamp, et al.
Diagnostic Microbiology and Infectious Disease|February 6, 2008
Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serumBrian T Tsuji, Steven N Leonard, Paul R Rhomberg, et al.
Pageof 54